Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial
Many patients with stage 1 hypertension have difficulties to achieve lifestyle changes to avoid the progression of the disease. The use of natural alternatives with demonstrated blood pressure-regulating properties is instrumental at this stage, avoiding the side effects found in some pharmaceutical...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Journal of Functional Foods |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1756464621002322 |
id |
doaj-516ddee6d4254d21bf2d4b1c3d8949f2 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marina Boix-Castejón María Herranz-López Mariló Olivares-Vicente Paula Campoy Nuria Caturla Jonathan Jones Juan M. Zazo Enrique Roche Vicente Micol |
spellingShingle |
Marina Boix-Castejón María Herranz-López Mariló Olivares-Vicente Paula Campoy Nuria Caturla Jonathan Jones Juan M. Zazo Enrique Roche Vicente Micol Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial Journal of Functional Foods Pre-hypertension Continuous blood pressure monitoring Body fat Systolic/diastolic blood pressure Dipper status Polyphenols |
author_facet |
Marina Boix-Castejón María Herranz-López Mariló Olivares-Vicente Paula Campoy Nuria Caturla Jonathan Jones Juan M. Zazo Enrique Roche Vicente Micol |
author_sort |
Marina Boix-Castejón |
title |
Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial |
title_short |
Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial |
title_full |
Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial |
title_fullStr |
Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial |
title_full_unstemmed |
Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial |
title_sort |
effect of metabolaid® on pre- and stage 1 hypertensive patients: a randomized controlled trial |
publisher |
Elsevier |
series |
Journal of Functional Foods |
issn |
1756-4646 |
publishDate |
2021-09-01 |
description |
Many patients with stage 1 hypertension have difficulties to achieve lifestyle changes to avoid the progression of the disease. The use of natural alternatives with demonstrated blood pressure-regulating properties is instrumental at this stage, avoiding the side effects found in some pharmaceutical drugs. In this context, previous studies have indicated the possibility that a botanical nutraceutical product based on the combination of Lippia citriodora and Hibiscus sabdariffa extracts has hypotensive properties in overweight and obese individuals. Therefore, we aimed to evaluate the antihypertensive properties of this dietary supplement, as well as the effect on anthropometric and circulating parameters in pre-hypertensive and early stage 1 hypertensive patients (n = 84). The nutraceutical product, rich in polyphenolic compounds, has been assessed in a 6-week randomized, double-blind, placebo-controlled trial with pre-hypertensive and early stage 1 hypertensive (non-medicated) individuals. Participants consumed early in the morning in fasting conditions 2 capsules/day containing each one 250 mg of the polyphenolic extracts. Anthropometric and blood parameters as well as punctual and continuous blood pressure monitoring were determined in placebo and experimental groups. As a result and compared to baseline values, volunteers showed a significant reduction of average daily systolic/diastolic blood pressure as well as in daytime diastolic/systolic, nighttime diastolic blood pressure and in % dipper. Intergroup analysis revealed that the consumption of the plant extract resulted in a significant reduction of body fat content (−1.26%; p < 0.05) and nocturnal systolic blood pressure (−16.60 mmHg; p < 0.05) as well as an improvement of the dipper status (3.18%; p < 0.01). In conclusion, these results suggest that the nutraceutical acts as a main regulator of the individual's blood pressure towards healthier values, and therefore may be useful for pre-hypertensive/pre-medicated individuals. |
topic |
Pre-hypertension Continuous blood pressure monitoring Body fat Systolic/diastolic blood pressure Dipper status Polyphenols |
url |
http://www.sciencedirect.com/science/article/pii/S1756464621002322 |
work_keys_str_mv |
AT marinaboixcastejon effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial AT mariaherranzlopez effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial AT mariloolivaresvicente effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial AT paulacampoy effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial AT nuriacaturla effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial AT jonathanjones effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial AT juanmzazo effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial AT enriqueroche effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial AT vicentemicol effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial |
_version_ |
1721306342862356480 |
spelling |
doaj-516ddee6d4254d21bf2d4b1c3d8949f22021-07-13T04:09:01ZengElsevierJournal of Functional Foods1756-46462021-09-0184104583Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trialMarina Boix-Castejón0María Herranz-López1Mariló Olivares-Vicente2Paula Campoy3Nuria Caturla4Jonathan Jones5Juan M. Zazo6Enrique Roche7Vicente Micol8Institute of Bioengineering and Department of Applied Biology-Nutrition, University Miguel Hernandez, Alicante Institute for Health and Biomedical Research (ISABIAL Foundation), Alicante, SpainInstituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Miguel Hernández University (UMH), Elche 03202, Alicante, Spain; Corresponding author at: Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche, Universidad Miguel Hernández, Avda. de la Universidad S/N◦, 03202 Elche, Alicante, Spain.Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Miguel Hernández University (UMH), Elche 03202, Alicante, SpainInstituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Miguel Hernández University (UMH), Elche 03202, Alicante, SpainMonteloeder SL, C/Miguel Servet 16, Nave 17, 03203 Elche, Alicante, SpainMonteloeder SL, C/Miguel Servet 16, Nave 17, 03203 Elche, Alicante, SpainRaval Health Center, Elche, Alicante, SpainInstitute of Bioengineering and Department of Applied Biology-Nutrition, University Miguel Hernandez, Alicante Institute for Health and Biomedical Research (ISABIAL Foundation), Alicante, Spain; CIBER, Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, SpainInstituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Miguel Hernández University (UMH), Elche 03202, Alicante, Spain; CIBER, Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, SpainMany patients with stage 1 hypertension have difficulties to achieve lifestyle changes to avoid the progression of the disease. The use of natural alternatives with demonstrated blood pressure-regulating properties is instrumental at this stage, avoiding the side effects found in some pharmaceutical drugs. In this context, previous studies have indicated the possibility that a botanical nutraceutical product based on the combination of Lippia citriodora and Hibiscus sabdariffa extracts has hypotensive properties in overweight and obese individuals. Therefore, we aimed to evaluate the antihypertensive properties of this dietary supplement, as well as the effect on anthropometric and circulating parameters in pre-hypertensive and early stage 1 hypertensive patients (n = 84). The nutraceutical product, rich in polyphenolic compounds, has been assessed in a 6-week randomized, double-blind, placebo-controlled trial with pre-hypertensive and early stage 1 hypertensive (non-medicated) individuals. Participants consumed early in the morning in fasting conditions 2 capsules/day containing each one 250 mg of the polyphenolic extracts. Anthropometric and blood parameters as well as punctual and continuous blood pressure monitoring were determined in placebo and experimental groups. As a result and compared to baseline values, volunteers showed a significant reduction of average daily systolic/diastolic blood pressure as well as in daytime diastolic/systolic, nighttime diastolic blood pressure and in % dipper. Intergroup analysis revealed that the consumption of the plant extract resulted in a significant reduction of body fat content (−1.26%; p < 0.05) and nocturnal systolic blood pressure (−16.60 mmHg; p < 0.05) as well as an improvement of the dipper status (3.18%; p < 0.01). In conclusion, these results suggest that the nutraceutical acts as a main regulator of the individual's blood pressure towards healthier values, and therefore may be useful for pre-hypertensive/pre-medicated individuals.http://www.sciencedirect.com/science/article/pii/S1756464621002322Pre-hypertensionContinuous blood pressure monitoringBody fatSystolic/diastolic blood pressureDipper statusPolyphenols |